Highest-materiality recent filing
4DMT Q2 net loss $72.9M; 4D-150 Phase 3 enrollment complete, $200M credit facility
Net loss $72.9M vs $54.7M; R&D expenses $68.3M vs $48.0M; G&A $12.5M vs $11.5M.
Overall cohort: 78% reduction in treatment burden (2.7 mean supplemental injections vs 12.0 projected for aflibercept Q8W).
4D Molecular Therapeutics secures up to $200M term loan facility with Hercules Capital
Initial $20M drawn at closing; additional tranches available up to $200M total, maturing June 1, 2031.
Directors elected: Nancy Miller-Rich (35.9M for, 1.2M withheld), John Milligan (35.8M for, 1.3M withheld), Shawn Tomasello (30.5M for, 6.6M withheld). Broker non-votes ~7.0M.
4DMT Q1 net loss $68.8M; cash $458M; 4D-150 Phase 3 enrollment complete
Cash $458M as of Mar 31, 2026, down from $514M; expected to fund ops into H2 2028.
4DMT appoints CFO Kristian Humer as Principal Accounting Officer
Appointment effective March 25, 2026; Humer succeeds Ashoo Gupta.
4DMT FY2025 net loss $140M; cash $514M; 4D-150 Phase 3 enrollment completed
Net loss of $140M in FY2025 versus $161M in FY2024; R&D expenses $196M (up from $141M).
4D Molecular Therapeutics exchanges 6.6M shares for pre-funded warrants with RA Capital and BVF
RA Capital exchanged 4,850,000 shares for a warrant to acquire 4,850,000 shares.
Fariborz Kamal resigned as President/COO effective Dec 31, 2025; transitions to part-time Chief Technical Advisor.
Target enrollment for 4FRONT-1 and 4FRONT-2 Phase 3 trials raised from 400 to 480 patients each.
4D Molecular Therapeutics appoints Kristian Humer as CFO effective Nov 17, 2025
Kristian Humer, formerly CFO at Foghorn Therapeutics and Viridian Therapeutics, joins as CFO and Principal Financial Officer.
4DMT reports Q3 net loss $56.9M, enters Otsuka partnership for 4D-150 APAC rights for $85M upfront
Net loss $56.9M in Q3 2025 vs $43.8M in Q3 2024; R&D expenses $49.4M (up from $38.5M).
Sold 8,385,809 shares at $10.51/share and 1,128,949 pre-funded warrants at $10.5099 each.
Preliminary cash, equivalents and marketable securities $372.2M as of Sept 30, 2025.
4D Molecular Therapeutics (FDMT) signs $85M upfront license deal with Otsuka for 4D-150 in APAC
Upfront cash payment of $85M from Otsuka; additional cost sharing of at least $50M over next three years.
4D Molecular Therapeutics appoints Ashoo Gupta as Principal Financial Officer
Ashoo Gupta appointed Principal Financial Officer and Principal Accounting Officer effective September 30, 2025.
4DMT Q2 net loss $54.7M; accelerates 4D-150 Phase 3 wet AMD data to H1 2027
Cash $417M (down from $505M Dec 2024); funds into 2028; workforce cut ~25% saves ~$15M/yr.
4D Molecular Therapeutics reduces workforce 25%, accelerates wet AMD data to H1 2027; CFO resigns
CFO Uneek Mehra resigns effective July 15; remains principal financial officer through September 2025 and Q2 filing.
4D Molecular Therapeutics annual meeting results: all four proposals approved
Stockholders elected Jacob Chacko, Susannah Gray, and Charles Theuer as Class II directors.
4DMT Q1 net loss $48M; initiates 4D-150 Phase 3 in wet AMD; cash runway to 2028
Net loss $48.0M vs $32.4M YoY; R&D expenses $40.7M (+46% YoY) due to Phase 3 startup.
4DMT reports FY2024 net loss of $160.9M; cash $505M; Phase 3 programs on track
Net loss of $160.9M in 2024 vs $100.8M in 2023; R&D expenses $141.3M (up 46% YoY).
4D Molecular reports positive 52-week Phase 2b data for wet AMD therapy 4D-150
Phase 2b (n=30): 83% reduction in supplemental aflibercept injections (0.97 mean vs 6.0 on-label); 57% injection-free over 52 weeks.
4D Molecular reports positive 32-week DME data; FDA aligns on single Phase 3; cash runway into 2028
Cash, equivalents, securities $506M as of Dec 31; cash runway extended to 2028.
RA Capital exchanges 535k FDMT shares for pre-funded warrant at $0.0001 strike
RA Capital Healthcare Fund exchanged 535,000 shares of common stock for a pre-funded warrant to purchase 535,000 shares at $0.0001 per share.
4DMT reports Q3 2024 net loss $43.8M, cash $551M; 4D-150 Phase 3 on track for Q1 2025
Net loss $43.8M (vs $10.3M Q3 2023); R&D expense $38.5M (vs $25.1M) on trial progression.
4D-150 shows up to 98% injection reduction in wet AMD; Phase 3 4FRONT expected Q1 2025
Phase 2b Broad (n=30): 89% annualized injection reduction, 80% with 0 or 1 injection, 70% injection-free at 52 weeks.
Cash and equivalents $578M as of June 30, 2024; expected to fund operations into H1 2027.
Interim data from Phase 1/2 PRISM trial (Dose Expansion, Phase 2 Dose Expansion, Phase 2 Population Expansion cohorts) expected at September 2024 medical conference.
Planned Phase 3 dose (3E10 vg/eye): 89% reduction in mean annualized injection rate; 77% injection-free at 24 weeks.
4D Molecular Therapeutics enters $250M ATM equity distribution agreement with Leerink Partners
Company enters Sales Agreement to sell up to $250M common stock via at-the-market offering through Leerink Partners.
David Kirn, M.D. elected as Class I director with 35,630,613 votes for, 7,849,441 withheld, and 1,574,659 broker non-votes.
4DMT Q1 2024 net loss $32.4M; advances 4D-150 toward Phase 3 for wet AMD
Net loss $32.4M in Q1 2024 vs $28.7M in Q1 2023.
4DMT reports FY2023 net loss $100.8M; positive 4D-150 wet AMD data, Phase 3 plan Q1 2025
Net loss $100.8M in 2023; cash $299M at Dec 2023; Feb 2024 offering $281M net; runway into H1 2027.
4D Molecular Therapeutics raises ~$281.4M in public offering of common stock and pre-funded warrants
Sold 6,586,015 shares at $29.50/share and pre-funded warrants for 3,583,476 shares at $29.4999 each.
Noriyuki Kasahara, M.D., Ph.D., appointed CSO effective January 2, 2024.
4D Molecular Therapeutics amends bylaws to update advance notice procedures
Board amended and restated bylaws on November 16, 2023.
Net loss of $10.3M versus $25.7M in Q3 2022; decrease primarily due to $20M upfront from Astellas License Agreement.
CFO August Moretti retires; Uneek Mehra appointed as CFO effective Sept 11, 2023
August J. Moretti retired as CFO effective Sept 11, 2023; will serve as Senior Business Advisor through 2023 then consultant through Dec 2024 at $18k/month.
Q2 net loss $29.6M ($28.1M prior year); R&D expense $23.6M; cash $310M as of June 30, 2023.
$20M upfront from Astellas; eligible for up to $42.5M in option/target substitution fees and $300M per target in milestones.
At May 23 annual meeting, 27,970,603 of 33,235,726 outstanding shares voted, representing 84.1% quorum.
4DMT reports Q1 net loss $28.7M; cash runway into H1 2026 after $129M offering
Net loss $28.7M for Q1 2023 vs $26.3M in Q1 2022; R&D expenses $22.4M.
4D Molecular Therapeutics closes $129.1M public offering of 8.625M shares at $16/share
Sold 7.5M firm shares plus 1.125M overallotment shares at $16.00 per share, netting ~$129.1M.
4DMT reports FY22 net loss of $107.5M; cash runway into H1 2025; pipeline advances
Net loss $107.5M in 2022 (vs $71.3M in 2021); revenue $3.1M (vs $18.0M) due to Roche collaboration end.
FDA clears IND for 4D-150 DME trial; places clinical hold on 4D-310 Fabry program after aHUS cases
FDA cleared IND for 4D-150 in diabetic macular edema; Phase 2 SPECTRA trial enrollment expected Q3 2023.
4DMT reports pipeline progress; Fabry trial halted after aHUS, FDA aligns on endpoints
Filed IND for Phase 2 SPECTRA trial of 4D-150 in DME; enrollment expected Q3 2023.
Cash, cash equivalents and marketable securities totaled $239M; runway into first half of 2025.
Appointed Noriyuki Kasahara, M.D., Ph.D., to Board as Class I director and Chair of Science and Technology Committee.
Net loss of $28.1M in Q2 2022 vs $7.6M in Q2 2021; revenue fell to $0.2M from $14.6M.
Board amended bylaws on June 14, 2022 to incorporate universal proxy rules for director nominations.
Effective as of January 2, 2024, Noriyuki Kasahara, M.D., Ph.D., has been appointed by the Board of Directors (the “Board”) of 4D Molecular Therapeutics, Inc. (the “Company”) as Chief Scientific Officer of the Company.
announced that Uneek Mehra had joined the Company as Chief Financial and Business Officer, Principal Financial Officer, Principal Accounting Officer, and Assistant Secretary of the Company.
announced that August J. Moretti will retire as Chief Financial Officer and Assistant Secretary of the Company, effective September 11, 2023.
appointed Fred Kamal, Ph.D., the Company’s current Chief Operating Officer and Chief Technical Officer, as President and Chief Operating Officer of the Company
appointed Noriyuki Kasahara, M.D., Ph.D., to the Board as a Class I director
On February 17, 2022, David Schaffer, Ph.D. delivered notice of his resignation from the Board of Directors (the "Board") of 4D Molecular Therapeutics, Inc. (the "Company") including his roles on the Nominating and Corporate Governance Committee and Science & Technology Committee, effective immediately.
Max materiality 0.85 · Median 0.65 · Most common event other_material